GOSS vs. SVA, ALBO, PRAX, FDMT, ETNB, CRON, NUVB, COGT, MESO, and DNTH
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Sinovac Biotech (SVA), Albireo Pharma (ALBO), Praxis Precision Medicines (PRAX), 4D Molecular Therapeutics (FDMT), 89bio (ETNB), Cronos Group (CRON), Nuvation Bio (NUVB), Cogent Biosciences (COGT), Mesoblast (MESO), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector.
Sinovac Biotech (NASDAQ:SVA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Gossamer Bio's return on equity of 0.00% beat Sinovac Biotech's return on equity.
81.2% of Gossamer Bio shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 5.0% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Gossamer Bio had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Gossamer Bio and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.76 beat Gossamer Bio's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.
Sinovac Biotech has higher revenue and earnings than Gossamer Bio.
Sinovac Biotech received 110 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 67.99% of users gave Sinovac Biotech an outperform vote while only 65.63% of users gave Gossamer Bio an outperform vote.
Gossamer Bio has a consensus target price of $7.88, indicating a potential upside of 603.13%. Given Sinovac Biotech's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Sinovac Biotech.
Summary
Sinovac Biotech beats Gossamer Bio on 7 of the 12 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
